462 related articles for article (PubMed ID: 16840343)
1. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
2. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
[TBL] [Abstract][Full Text] [Related]
3. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
4. IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells.
Mohanram V; Sköld AE; Bächle SM; Pathak SK; Spetz AL
J Immunol; 2013 Apr; 190(7):3346-53. PubMed ID: 23427247
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells.
Wang FX; Huang J; Zhang H; Ma X; Zhang H
J Gen Virol; 2008 Mar; 89(Pt 3):722-730. PubMed ID: 18272764
[TBL] [Abstract][Full Text] [Related]
6. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
Tanaka Y; Marusawa H; Seno H; Matsumoto Y; Ueda Y; Kodama Y; Endo Y; Yamauchi J; Matsumoto T; Takaori-Kondo A; Ikai I; Chiba T
Biochem Biophys Res Commun; 2006 Mar; 341(2):314-9. PubMed ID: 16426578
[TBL] [Abstract][Full Text] [Related]
7. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
9. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
10. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
11. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system.
Argyris EG; Acheampong E; Wang F; Huang J; Chen K; Mukhtar M; Zhang H
Virology; 2007 Oct; 367(2):440-51. PubMed ID: 17631933
[TBL] [Abstract][Full Text] [Related]
12. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
13. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G & HTLV-1: inhibition without deamination.
Strebel K
Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
[TBL] [Abstract][Full Text] [Related]
15. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
16. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
Jost S; Turelli P; Mangeat B; Protzer U; Trono D
J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
[TBL] [Abstract][Full Text] [Related]
17. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha.
Sarkis PT; Ying S; Xu R; Yu XF
J Immunol; 2006 Oct; 177(7):4530-40. PubMed ID: 16982890
[TBL] [Abstract][Full Text] [Related]
18. Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.
Lavender KJ; Gibbert K; Peterson KE; Van Dis E; Francois S; Woods T; Messer RJ; Gawanbacht A; Müller JA; Münch J; Phillips K; Race B; Harper MS; Guo K; Lee EJ; Trilling M; Hengel H; Piehler J; Verheyen J; Wilson CC; Santiago ML; Hasenkrug KJ; Dittmer U
J Virol; 2016 Jul; 90(13):6001-6013. PubMed ID: 27099312
[TBL] [Abstract][Full Text] [Related]
19. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
20. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]